Related references
Note: Only part of the references are listed.Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
Luigi Dolcetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Srinivas Nagaraj et al.
JOURNAL OF IMMUNOLOGY (2010)
Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians
Lindsey Enewold et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
C. Christian Johansson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The COX-2/PGE(2) pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough et al.
CARCINOGENESIS (2009)
Myeloid-derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions
Vincenzo Bronte
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development
Verena Greifenberg et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Suppressive Influences in the Immune Response to Cancer
Vincenzo Bronte et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Tumor escape mechanism governed by myeloid-derived suppressor cells
Srinivas Nagaraj et al.
CANCER RESEARCH (2008)
Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2008)
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
Ilaria Marigo et al.
IMMUNOLOGICAL REVIEWS (2008)
Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib plus chemotherapy - Cancer and leukemia group B trial 30203
Martin J. Edelman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics
Naoki Umemura et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases
Nidra I. Rodriguez et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Cytokine production of lung cancer cell lines:: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro
Takashi Fukuyama et al.
CANCER SCIENCE (2007)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
Pratima Sinha et al.
CANCER RESEARCH (2007)
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
N. L. P. Barnes et al.
BRITISH JOURNAL OF CANCER (2007)
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma
Augusto C. Ochoa et al.
CLINICAL CANCER RESEARCH (2007)
The role of cyclooxygenase-2 and prostaglandins in colon cancer
Annie L. Eisinger et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Celecoxib for the prevention of colorectal adenomatous polyps
Nadir Arber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. P. J. J. Hegmans et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer
T Hahn et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
V Ferrari et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Role of tumor-associated macrophages in tumor progression and invasion
Alberto Mantovani et al.
CANCER AND METASTASIS REVIEWS (2006)
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
PC Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Regulation of immune responses by L- arginine metabolism
V Bronte et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma:: Correlation with suppression of COX-2 synthesis
S Shishodia et al.
JOURNAL OF IMMUNOLOGY (2004)
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma
KJ O'Byrne et al.
LUNG CANCER (2004)
Cyclooxygenases in cancer: progress and perspective
S Zha et al.
CANCER LETTERS (2004)
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A Baldi et al.
THORAX (2004)
Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells
B Agarwal et al.
APOPTOSIS (2003)
Role of cyclooxygenase-2 in breast cancer
B Singh et al.
JOURNAL OF SURGICAL RESEARCH (2002)
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension
HF Cheng et al.
KIDNEY INTERNATIONAL (2002)
Immature myeloid cells and cancer-associated immune suppression
S Kusmartsev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1β-treated human synovial fibroblasts
WH Faour et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells:: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
S Sakaguchi et al.
IMMUNOLOGICAL REVIEWS (2001)
Share Paper
